What are semaglutide tablets used for — and who can take them?

What condition are semaglutide tablets licensed to treat?

The licensed use of Wegovy tablets is weight management in adults. Specifically, the MHRA licence covers adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who have at least one weight-related condition, for example, high blood pressure, raised cholesterol, obstructive sleep apnoea or prediabetes. The tablets are intended to work alongside a reduced-calorie diet and increased physical activity, not instead of them.

It is worth being precise about what this licence does not cover. Rybelsus (another oral semaglutide product) is licensed exclusively for type 2 diabetes and is dispensed at different strengths entirely. If you have come across references to 3 mg, 7 mg or 14 mg semaglutide tablets, those are Rybelsus strengths. The Wegovy weight-loss tablet ladder is 1.5 mg, 4 mg, 9 mg and 25 mg only. A question our prescribers hear most weeks is whether someone can use Rybelsus for weight loss: the short answer is no, the licences are separate, and a prescriber must choose the right product for the right indication.

You can read more about the full picture of semaglutide tablets available in the UK to understand how these products sit alongside each other.

How does the tablet actually produce weight loss?

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone released after eating; it tells the brain you are full, slows the pace at which the stomach empties, and reduces the drive to keep eating. The tablet formulation pairs semaglutide with an absorption enhancer called SNAC, which allows the medicine to be absorbed through the stomach lining even though GLP-1 medicines are normally broken down in the gut before they reach the bloodstream.

Because the tablet is absorbed in the stomach rather than the small intestine, how you take it matters considerably. It should be the first thing in the morning, swallowed whole with no more than around 120 ml of plain water, at least 30 minutes before food, drink (including coffee) or any other oral medicine. Missing that window or taking it with a full glass of water can reduce absorption meaningfully. The MHRA-approved patient information leaflet has the precise instructions, and your prescriber will go through this with you.

One practical advantage over the weekly injection is storage: the tablet does not need refrigeration, which makes it considerably easier to manage when travelling or at work. For a broader look at the evidence base, the semaglutide tablets for weight loss page covers the trial results in more detail.

What does the clinical trial evidence show about how well the tablets work?

The pivotal trial was OASIS 4, a phase 3 study involving 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. Participants were randomised to the 25 mg oral semaglutide or placebo alongside lifestyle support. The average weight reduction in the semaglutide group was around 13.6%, compared with roughly 2.4% in the placebo group. Among participants who stayed fully adherent to treatment throughout the trial, the figure reached approximately 17%, though that is the adherent-group figure, not the overall average, and framing matters here.

Most common side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported in about 74% of the semaglutide group versus 42% of the placebo group. These were generally mild to moderate and tended to ease as the dose settled. If you want a closer look at how semaglutide tablet use works in practice, including dosing instructions and what to expect at each stage, that page goes into the detail. The MHRA's approval announcement from 11 June 2026 sets out the regulatory basis for these findings.

The Wegovy 25 mg tablet sits in the same family as the Wegovy 25 mg tablet, which you can explore in more detail if you want to understand the maintenance dose specifically. Cost context for private treatment is covered on the weight-loss treatments page.

Is this medicine available on the NHS, and who is it suitable for?

At the time of writing, Wegovy tablets are not available on the NHS. NICE would need to complete a formal appraisal before NHS commissioning could begin, and that process takes time. The injectable form of Wegovy (semaglutide 2.4 mg weekly) does have a NICE recommendation under NICE technology appraisal TA875, but that appraisal is specific to the injection and does not extend to the tablet formulation. Private prescription is currently the only route.

Suitability is always an individual clinical decision. The prescriber looks at BMI, relevant health conditions, current medicines, medical history and whether you have any contraindications. The tablets are not licensed for use during pregnancy, breastfeeding or when trying to conceive, and they are not licensed for under-18s. If you are unsure whether your circumstances fall within the recognised uses of semaglutide tablets, that is exactly the kind of question to raise openly during your consultation. If you take oral contraceptives, there may be additional considerations around timing, worth raising explicitly with your prescriber.

If you would like to understand more about how the service works before deciding anything, our about us page sets out how nume, sorry, how the Wegovy pill fits into what we offer as a clinician-led pharmacy. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber on the day it is submitted. Check your eligibility by starting your free consultation.